Adaptive Biotechnologies ADPT Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's change in deferred revenue?
- Adaptive Biotechnologies (ADPT) reported change in deferred revenue of $4M in Q1 2026.
- How has Adaptive Biotechnologies's change in deferred revenue changed year-over-year?
- Adaptive Biotechnologies's change in deferred revenue increased by 220.4% year-over-year, from -$3.33M to $4M.
- What is the long-term trend for Adaptive Biotechnologies's change in deferred revenue?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's change in deferred revenue has grown at a -8.5% compound annual growth rate (CAGR), from -$57.73M to -$40.4M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.